Cipla gets no USFDA observations for Indore facility Farhat Nasim18 May 2019 4:15 AM GMTThe US health regulator conducted a post-approval inspection at Cipla Ltd's Indore facility from 13th May to 17th May 2019. New Delhi: Drug firm Cipla...
China war on healthcare costs lure Indian drugmaker Sun Pharma: Report Medical Dialogues Bureau6 May 2019 3:45 AM GMTChina has rolled out an ambitious multi-city bulk procurement program that's driving down prices and providing an opening for Indian manufacturers...
NPPA fixes retail price of 20 drugs including FDCs for Blood pressure control, dual antiplatelet Meghna A Singhania4 May 2019 7:01 AM GMTNew Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail...
Cipla gets USFDA nod for Ambrisentan tablets to treat pulmonary arterial hypertension Farhat Nasim30 April 2019 4:30 AM GMTCipla's Ambrisentan tablets 5 mg and 10 mg is AB-rated generic therapeutic equivalent version of Gilead Sciences Inc's Letairis.New Delhi: Drug major...
Cipla appoints Dr Raju Mistry as Global Chief People Officer Medical Dialogues Bureau23 April 2019 3:45 AM GMTIn her role at Cipla, Raju Mistry will oversee Human Resources, and Administration and Facilities Management. She will be a member of the Management...
Cipla acquires 30 percent stake in Brandmed for Rs 32 crore Garima18 April 2019 3:45 AM GMTThe acquisition of Brandmed is expected to complete by May 31. The transaction worth Rs 32 crore will be executed by the company's South African arm...
Cipla, Pulmatrix join hands to co-develop Pulmazole for treating asthma Garima16 April 2019 4:10 AM GMTPulmazole an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in...
CDSCO expert committee suggests ban of yet another 324 FDCs Meghna A Singhania15 April 2019 6:19 AM GMTNew Delhi: Domestic drugmakers are likely to face a blow as 324 Fixed Dose Combination (FDCs) drugs have been recommended to be banned by an expert...
Cipla launches respiratory inhalation therapy product Niveoli in India Farhat Nasim12 April 2019 6:11 AM GMTNew Delhi: Drug major Cipla Friday announced the launch of its proprietary respiratory inhalation therapy product 'Niveoli' in India. Niveoli is used...
Cipla signs over Rs 152 crore pact with Pulmatrix for new asthma drug Pulmazole Garima2 April 2019 4:15 AM GMTThe agreement has been signed between the company's wholly-owned subsidiary in the US, Cipla Technologies LLC with Pulmatrix Inc for investment in...
Cipla gets 8 USFDA observations for Kurkumbh plant Farhat Nasim1 April 2019 4:25 AM GMTThe inspection covered three units at the plant. Post the conclusion of the inspection, the company received 8 GMP observations. The company also...
Government must have compulsive licensing for essential drugs : Chairman, Cipla Farhat Nasim8 March 2019 4:00 AM GMTCipla Chairman, Y K Hamied said that many drugs which are not covered under patent should be made in India which is not happening at present, citing...
